Patents Assigned to CIRCUIT THERAPEUTICS, INC.
  • Patent number: 11103723
    Abstract: Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and/or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: August 31, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Circuit Therapeutics, Inc.
    Inventors: Karl A. Deisseroth, Elizabeth R. Aden, Viviana Gradinaru, Scott L. Delp
  • Publication number: 20200139151
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: January 15, 2020
    Publication date: May 7, 2020
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Fred Moll, Alexander K. Arrow
  • Publication number: 20200114162
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Greg Stahler, Ananya Mitra, Joyce Huang, Dan Andersen, Alexander K. Arrow, David Moore
  • Publication number: 20200009397
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 9, 2020
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Karl Deisseroth, Fred Moll, Dan Andersen, Alexander K. Arrow
  • Publication number: 20190388700
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: April 12, 2019
    Publication date: December 26, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Scott Delp, Karl Deisseroth, Dan Andersen
  • Publication number: 20190391347
    Abstract: Configurations are described for creating and using separable optical feedthroughs. These are especially useful in their at least semi-hermetic form when integrated with implantable photomedical devices. One embodiment is directed to a system for operatively coupling an optical output from a light source positioned inside of a sealed housing to an external optical fiber, comprising: a first optical fiber disposed adjacent to the light source and configured to receive at least a portion of the optical output; a second optical fiber operatively coupled to the first optical fiber and configured to capture at least a portion of an output from the first optical fiber; a primary seal operatively coupled to the housing between the light source and the second optical fiber that is at least partially transparent; and a secondary seal positioned between the second optical fiber and the environment.
    Type: Application
    Filed: September 3, 2019
    Publication date: December 26, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Greg Stahler, David Angeley, Brian Andrew Ellingwood
  • Patent number: 10512787
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: December 24, 2019
    Assignee: Circuit Therapeutics, Inc.
    Inventors: Scott Delp, Karl Deisseroth, Dan Andersen
  • Publication number: 20190321473
    Abstract: One embodiment is directed to a method for treating the nervous system of a patient, comprising: determining a desired nervous system functional modulation to be facilitated by sonogenetic intervention; selecting targeted neuroanatomy for achieving the desired functional outcome with sonogenetic intervention; and delivering an effective amount of polynucleotide comprising a sound-responsive opsin protein which is expressed in neurons of the targeted neuroanatomy, wherein delivering comprises systemically injecting the effective amount of polynucleotide and facilitating diffusive access to the targeted neuroanatomy using focused ultrasound energy.
    Type: Application
    Filed: April 2, 2019
    Publication date: October 24, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Christopher L. Towne, Dan E. Andersen
  • Publication number: 20190275169
    Abstract: One embodiment is directed to a method for treating the nervous system of a patient, comprising: determining a desired nervous system functional modulation to be facilitated by optogenetic intervention; selecting targeted neuroanatomy for achieving the desired functional outcome with optogenetic intervention; and delivering an effective amount of polynucleotide comprising a light-responsive opsin protein which is expressed in neurons of the targeted neuroanatomy, and delivering an effective amount of immunosuppressant.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 12, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Christopher L. Towne, Claire Discenza, Sean McCormack
  • Publication number: 20190240500
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitve proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Karl Deisseroth, Fred Moll, Dan Andersen, Alexander K. Arrow
  • Publication number: 20190224492
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Scott Delp, Karl Deisseroth, Dan Andersen
  • Publication number: 20190217128
    Abstract: One embodiment is directed to an implantable probe system for delivering acoustical energy to a targeted tissue portion of a patient, comprising: a plurality of substrate portions, each substrate portion comprising at least one acoustical emitter; a probe body portion having proximal and distal ends and being movably coupled to the plurality of substrates and configured to at least partially encapsulate the plurality of substrates; and a distal end portion coupled to the distal end of the probe body portion, the distal end portion comprising at least one guiding feature configured to redirect a path of at least one of the substrate portions as such substrate portion is extended through and past the distal end portion by moving the plurality of substrates relative to the probe body portion
    Type: Application
    Filed: January 16, 2019
    Publication date: July 18, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Brian Andrew Ellingwood, Brian Beckey, Christopher L. Towne, Dan Andersen
  • Publication number: 20190217129
    Abstract: One embodiment is directed to a method for acoustically modulating activity of cells comprising a targeted tissue portion of a patient. An implantable probe system may be utilized for delivering acoustical energy to a targeted tissue portion of a patient, comprising a plurality of substrate portions, each substrate portion comprising at least one acoustical emitter; a probe body portion having proximal and distal ends and being movably coupled to the plurality of substrates and configured to at least partially encapsulate the plurality of substrates; and a distal end portion coupled to the distal end of the probe body portion, the distal end portion comprising at least one guiding feature configured to redirect a path of at least one of the substrate portions as such substrate portion is extended through and past the distal end portion by moving the plurality of substrates relative to the probe body portion.
    Type: Application
    Filed: January 16, 2019
    Publication date: July 18, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Brian Andrew Ellingwood, Brian Beckey, Christopher L. Towne, Dan Andersen
  • Publication number: 20190209709
    Abstract: One embodiment is directed to a system for altering the function of a sensory unit that innervates a targeted tissue region in an animal, the sensory unit being configured to express a light-responsive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; and a light source configured to provide light to the light delivery element; wherein the targeted tissue structure is illuminated transcutaneously with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light-responsive protein to the radiation.
    Type: Application
    Filed: March 21, 2019
    Publication date: July 11, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Christopher L. Towne, Dan Andersen
  • Patent number: 10307609
    Abstract: The present disclosure provides compositions and methods for controlling pain. The present disclosure provides methods for identifying agents that control pain.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: June 4, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Circuit Therapeutics, Inc.
    Inventors: Shrivats Mohan Iyer, Scott L. Delp, Kathryn L. Montgomery, Karl A. Deisseroth, Christopher Towne
  • Publication number: 20190160300
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: May 30, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Scott Delp, Karl Deisseroth, Dan Andersen
  • Publication number: 20190129111
    Abstract: Configurations are described for creating and using separable optical feedthroughs. These are especially useful in their at least semi-hermetic form when integrated with implantable photomedical devices. One embodiment is directed to a system for operatively coupling an optical output from a light source positioned inside of a sealed housing to an external optical fiber, comprising: a first optical fiber disposed adjacent to the light source and configured to receive at least a portion of the optical output; a second optical fiber operatively coupled to the first optical fiber and configured to capture at least a portion of an output from the first optical fiber; a primary seal operatively coupled to the housing between the light source and the second optical fiber that is at least partially transparent; and a secondary seal positioned between the second optical fiber and the environment.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 2, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Greg Stahler, David Angeley, Brian Andrew Ellingwood
  • Publication number: 20190117993
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: January 2, 2019
    Publication date: April 25, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Karl Deisseroth, Fred Moll, Dan Andersen, Alexander K. Arrow
  • Publication number: 20190105507
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 11, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: Greg Stahler, Dan Andersen, Joyce Huang, David C. Lundmark, David Moore
  • Publication number: 20190099611
    Abstract: Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 4, 2019
    Applicant: Circuit Therapeutics, Inc.
    Inventors: David C. Lundmark, Fred Moll, Alexander K. Arrow